Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Conservative management of endometrial cancer: a survey amongst European clinicians.

La Russa M, Zapardiel I, Halaska MJ, Zalewski K, Laky R, Dursun P, Lindquist D, Sukhin V, Polterauer S, Biliatis I.

Arch Gynecol Obstet. 2018 Aug;298(2):373-380. doi: 10.1007/s00404-018-4820-7. Epub 2018 Jun 26.

PMID:
29943129
2.

Occult myometrial recurrence after progesterone therapy to preserve fertility in a young patient with endometrial cancer.

Hurst SA, Hartzfeld KM, Del Priore G.

Fertil Steril. 2008 Mar;89(3):724.e1-3. Epub 2007 Jun 13.

PMID:
17570366
3.

Hormonal therapy for women with stage IA endometrial cancer of all grades.

Park JY, Kim DY, Kim TJ, Kim JW, Kim JH, Kim YM, Kim YT, Bae DS, Nam JH.

Obstet Gynecol. 2013 Jul;122(1):7-14. doi: 10.1097/AOG.0b013e3182964ce3.

PMID:
23743459
4.

Hysteroscopic Resection in Fertility-Sparing Surgery for Atypical Hyperplasia and Endometrial Cancer: Safety and Efficacy.

De Marzi P, Bergamini A, Luchini S, Petrone M, Taccagni GL, Mangili G, Colombo G, Candiani M.

J Minim Invasive Gynecol. 2015 Nov-Dec;22(7):1178-82. doi: 10.1016/j.jmig.2015.06.004. Epub 2015 Jun 16.

PMID:
26092080
5.

Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer.

Chen M, Jin Y, Li Y, Bi Y, Shan Y, Pan L.

Int J Gynaecol Obstet. 2016 Jan;132(1):34-8. doi: 10.1016/j.ijgo.2015.06.046. Epub 2015 Oct 1.

PMID:
26493012
6.

Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin.

Simpson AN, Feigenberg T, Clarke BA, Gien LT, Ismiil N, Laframboise S, Massey C, Ferguson SE.

Gynecol Oncol. 2014 May;133(2):229-33. doi: 10.1016/j.ygyno.2014.02.020. Epub 2014 Feb 19.

PMID:
24561246
7.

[Pregnant rate and pregnancy-relating factors of patients with early endometrial carcinoma and severe atypical hyperplasia of endometrium after fertility-preserving treatment by progestin].

Cao DY, Yu M, Yang JX, Shen K, Huang HF, Cheng NH, Sun ZY, Deng CY, Yu Q, He FF.

Zhonghua Fu Chan Ke Za Zhi. 2013 Jul;48(7):519-22. Chinese.

PMID:
24284224
8.

Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature.

Ohyagi-Hara C, Sawada K, Aki I, Mabuchi S, Kobayashi E, Ueda Y, Yoshino K, Fujita M, Tsutsui T, Kimura T.

Arch Gynecol Obstet. 2015 Jan;291(1):151-7. doi: 10.1007/s00404-014-3417-z. Epub 2014 Aug 14. Review.

PMID:
25118836
9.

Hysteroscopic resection in the management of early-stage endometrial cancer: report of 2 cases and review of the literature.

Arendas K, Aldossary M, Cipolla A, Leader A, Leyland NA.

J Minim Invasive Gynecol. 2015 Jan;22(1):34-9. doi: 10.1016/j.jmig.2014.08.782. Epub 2014 Sep 6. Review.

PMID:
25196160
10.

Conservative treatment with progestin and pregnancy outcomes in endometrial cancer.

Hahn HS, Yoon SG, Hong JS, Hong SR, Park SJ, Lim JY, Kwon YS, Lee IH, Lim KT, Lee KH, Shim JU, Mok JE, Kim TJ.

Int J Gynecol Cancer. 2009 Aug;19(6):1068-73. doi: 10.1111/IGC.0b013e3181aae1fb.

PMID:
19820370
11.

Factors affecting pregnancy outcomes in young women treated with fertility-preserving therapy for well-differentiated endometrial cancer or atypical endometrial hyperplasia.

Inoue O, Hamatani T, Susumu N, Yamagami W, Ogawa S, Takemoto T, Hirasawa A, Banno K, Kuji N, Tanaka M, Aoki D.

Reprod Biol Endocrinol. 2016 Jan 15;14:2. doi: 10.1186/s12958-015-0136-7.

12.

Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer.

Park JY, Nam JH.

Oncologist. 2015 Mar;20(3):270-8. doi: 10.1634/theoncologist.2013-0445. Epub 2015 Feb 11. Review.

13.

Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer.

Falcone F, Laurelli G, Losito S, Di Napoli M, Granata V, Greggi S.

J Gynecol Oncol. 2017 Jan;28(1):e2. doi: 10.3802/jgo.2017.28.e2. Epub 2016 Aug 8.

14.

Six months response rate of combined oral medroxyprogesterone/levonorgestrel-intrauterine system for early-stage endometrial cancer in young women: a Korean Gynecologic-Oncology Group Study.

Kim MK, Seong SJ, Kang SB, Bae DS, Kim JW, Nam JH, Lim MC, Lee TS, Kim S, Paek J.

J Gynecol Oncol. 2019 Mar;30(2):e47. doi: 10.3802/jgo.2019.30.e47. Epub 2019 Jan 7.

15.

Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer.

Mitsuhashi A, Sato Y, Kiyokawa T, Koshizaka M, Hanaoka H, Shozu M.

Ann Oncol. 2016 Feb;27(2):262-6. doi: 10.1093/annonc/mdv539. Epub 2015 Nov 16.

PMID:
26578736
16.

Dilatation and curettage is more accurate than endometrial aspiration biopsy in early-stage endometrial cancer patients treated with high dose oral progestin and levonorgestrel intrauterine system.

Kim DH, Seong SJ, Kim MK, Bae HS, Kim M, Yun BS, Jung YW, Shim JY.

J Gynecol Oncol. 2017 Jan;28(1):e1. doi: 10.3802/jgo.2017.28.e1. Epub 2016 Aug 2.

17.

Progestin re-treatment in patients with recurrent endometrial adenocarcinoma after successful fertility-sparing management using progestin.

Park JY, Lee SH, Seong SJ, Kim DY, Kim TJ, Kim JW, Kim JH, Kim YM, Kim YT, Bae DS, Nam JH.

Gynecol Oncol. 2013 Apr;129(1):7-11. doi: 10.1016/j.ygyno.2012.12.037. Epub 2012 Dec 30.

PMID:
23283299
18.

Prognostic factors of oncological and reproductive outcomes in fertility-sparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin in Chinese patients.

Zhou R, Yang Y, Lu Q, Wang J, Miao Y, Wang S, Wang Z, Zhao C, Wei L.

Gynecol Oncol. 2015 Dec;139(3):424-8. doi: 10.1016/j.ygyno.2015.09.078. Epub 2015 Sep 30.

PMID:
26428941
19.

[Conservative treatment of endometrial cancer as a way to preserve fertility. Five-year experience at Instituto Nacional de Perinatilogía Isidro Espinoza de los Reyes].

Arteaga Gómez AC, Castellanos Barroso G, Márquez Acosta G.

Ginecol Obstet Mex. 2012 Jun;80(6):394-9. Spanish.

PMID:
22826967
20.

A prospective study of fertility-sparing treatment with megestrol acetate following hysteroscopic curettage for well-differentiated endometrioid carcinoma and atypical hyperplasia in young women.

Shan BE, Ren YL, Sun JM, Tu XY, Jiang ZX, Ju XZ, Zang RY, Wang HY.

Arch Gynecol Obstet. 2013 Nov;288(5):1115-23. doi: 10.1007/s00404-013-2826-8. Epub 2013 May 5.

PMID:
23644919

Supplemental Content

Support Center